HIV JournalView

Table of Contents

• Poly-L-Lactic Acid for the Treatment of Facial Wasting
• The Impact of Patient Knowledge on HAART Initiation
• Antivirogram vs. PhenoSense Assays
• Immune Reconstitution Inflammatory Syndrome and HAART
• Drug Resistance as Measured by Single vs. Multiple Genotypic Tests Over Time
• A Review of Interactions Between Natural Health Products and HIV Medications
• HIV and Hepatitis C Coinfection
• Efficacy of Once-Daily Abacavir + Lamivudine + Tenofovir in Naive Patients

Poly-L-Lactic Acid for the Treatment of Facial Wasting

Lafaurie M, Dolivo M, Porcher R, Rudant J, Madelaine I, Molina J-M. Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J Acquir Immune Defic Syndr. April 1, 2005;38(4):393-398.

Lipodystrophy syndromes are one of the most common complications of current HIV treatment and are a cause of much distress for many patients. Lipodystrophy can take many forms, including lipoaccumulation and lipoatrophy. Although we know that facial lipoatrophy is characterized by maxillary or temporal wasting, the exact etiology or mechanism has yet to be elucidated. But it is clear that the dramatic changes caused by facial lipoatrophy result in significant self esteem and quality of life issues for patients. Since it's a combination of HIV itself and perhaps certain antiretrovirals more than others that causes this problem, various treatments and interventions, such as switching treatments, have not had much success at reversing or preventing the problem. This has led providers and their patients to seek other solutions.

...

Want to read the rest of this article? To learn more about our audience, we're asking readers to register in order to receive full access to all of our materials. Please click here to begin your quick, free registration at The Body PRO.

If you're already registered with The Body PRO, please log in:

E-mail Address
Password
	Remember my login

Forgot your password?